Assay.Works and ISAR Bioscience Team up to Develop Novel Regenerative Therapies
Combining stem cell and genomic engineering know-how to generate next generation disease models with extensive industry experience in High-Throughput Screening (HTS) and therapeutics discovery technologies will expand and diversify the portfolio and increase strategic capabilities.
PLANEGG, Germany - Aug. 1, 2019 - PRLog -- Assay.Works GmbH and ISAR Bioscience GmbH signed a collaboration agreement to jointly develop new therapeutics in the fields of regenerative medicine using state-of-the-
Projects will be sourced from the partners' own project portfolios and their networks. ISAR and Assay.Works will cooperate closely throughout the drug discovery process in alignment with their strategic collaboration partners. ISAR contributes its leading stem cell and genomic engineering know-how to generate next generation disease models and assay technologies that improve drug candidate discovery and validation as well as patient stratification in clinical trials. Assay.Works adds its proven lead discovery engine including a pharma-grade 150k library of lead-like and bioactive small molecules, cell-based and phenotypic assay technologies, and workflow automation to support the discovery and characterization of novel drug candidates.
"We are excited to partner with the scientific team at ISAR. Their stem cell platform perfectly fits our mission to develop and apply predictable and relevant assays for therapeutics discovery," says Johannes Knop, Assay.Works founder and COO. Ulrich Gerth, CEO of ISAR, continues: "Applied stem cell biology and genome engineering technologies have advanced enormously and enable development of disease models for complex diseases. We currently forge strategic partnerships with industry partners in priority areas to translate scientific breakthroughs into therapies. This agreement is highly valuable because Assay.Works brings in more than 15 years of profound industry experience in High-Throughput Screening (HTS) and therapeutics discovery technologies."
Dr. Johannes Knop
COO, Assay.Works GmbH
Tel: +49 (941) 2000 1240
Dr. Ulrich C. Gerth
CEO, ISAR Bioscience GmbH
Tel: +49 (89) 356475 400
Assay.Works is a contract research organization (CRO) providing research services to pharmaceutical/
Our mission is to accelerate our partner's research programs by developing and executing predictive and scalable assays to quantify the bioactivity of novel chemical and biological entities. We combine scientific rigor with our domain expertise in laboratory automation, informatics, and industry best practices to turn challenging assays into quantitative, reproducible results. Assay.Works' service portfolio includes Assay Development, Cell Line Engineering and Production of Cellular Reagents, Bioactivity Assessments, Quantitative Biology Applications, and High-Throughput Screening (HTS).
About ISAR Bioscience
ISAR Bioscience GmbH (ISAR:Institute for Stem Cell & Applied Regenerative MedicineResearch)
ISAR was founded in 2018 by scientists, drug discovery professionals, and science entrepreneurs who share the passion that immediate translation of scientific discoveries offers an unprecedented opportunity to discover and develop effective pharmaceutical therapeutics as well as industrial biotechnology products and at the same time enhance economic productivity of knowledge societies.
ISAR attracted an initial 20 Mio € funding from the Bavarian Ministry of Economic Affairs, Regional Development and Energy to support ISAR's translational R&D concept. Part of this substantial support will be dedicated for joint projects within the ISAR collaboration framework.
ISAR Bioscience GmbH
+49 89 356475 400